<h2></h2>
Open up the leading on blog posts to aide legibility. Lorem ipsum dolor sit amet. Non minima dolores eum voluptatem laborum et magni cupiditate est blanditiis fugiat ut ducimus voluptatibus. Et obcaecati praesentium et repellendus maiores sed amet autem. Sed quae debitis rem animi velit et maxime quia. <a href="http://google.com">Non minima dolores eum voluptatem</a> laborum et magni cupiditate est blanditiis fugiat ut ducimus voluptatibus. Et obcaecati praesentium et repellendus maiores sed amet autem. Sed quae debitis rem animi velit et maxime quia.
<h5>Header style here, with flexibility to use any H style</h5>
Lorem ipsum dolor et conecuit es ciao minima dolores eum voluptatem laborum et magni cupiditate est blanditiis fugiat ut ducimus voluptatibus. Et obcaecati praesentium et repellendus maiores sed amet autem. Sed quae debitis rem animi velit et maxime quia.  
<div id="attachment_350" style="width: 446px" class="wp-caption aligncenter"><img loading="lazy" decoding="async" aria-describedby="caption-attachment-350" class="wp-image-350 " src="http://healum.sd-clients.com/wp-content/uploads/2023/09/Image-300x219.png" alt="Attribution here for ermbeded imagery or videos" width="436" height="245" />Attribution here for ermbeded imagery or videos</div>
&nbsp;

Request a meeting

New blog post

<h3 class="elementor-heading-title elementor-size-default">Exploring the impact of a care planning software and app solution on the management of type 2 diabetes</h3>
The paper titled “A randomised control trial to explore the impact and efficacy of the Healum collaborative care planning software and app on condition management in the type 2 diabetes mellitus population in NHS primary care” (Heald et al, 2023a) examines the application of a specific supportive digital solution – the Healum Collaborative Care Planning Software and App – in improving health outcomes in individuals with type 2 diabetes through the delivery of personalised plans of care, support and education accessible on a mobile device. It highlights that the increasing number of people living with long-term conditions, such as type 2 diabetes, is one of the biggest challenges facing healthcare systems. With type 2 diabetes prevalence worldwide estimated to increase to 700 million by 2045, associated high costs and the complex lifestyle changes required for effective management, timely and scalable solutions to support its management at a distance are needed.
Diabetes specialist nurses (DSNs) and other healthcare professionals (HCPs) involved in diabetes management play a critical role in the care of people with diabetes by providing education, monitoring and support to aid the long-term management of this condition to prevent complications. However, diabetes teams face several challenges that may impact the quality of care they provide. There is an opportunity for personalised care planning to aid the team to combat these challenges.
1. Limited time and resources. DSNs and doctors have limited time and resources to provide care to people. This can be due to high numbers of people seeking treatment, understaffing or a lack of support staff. As a result, HCPs may struggle to provide adequate personalised care. This can lead to poorer outcomes and an increased risk of complications. By tailoring care plans to the most important unique needs of each individual, the diabetes team can ensure that people receive the most appropriate care for their condition, whilst also using their time more effectively.
2. Education. Education is critical to diabetes care, as individuals need to understand how to manage their condition to prevent complications. DSNs may struggle to provide optimal education owing to time constraints, language barriers or a lack of individuals’ engagement. Engaging people in their own care can be especially challenging, particularly if they are resistant to making changes to their lifestyle or treatment plan. This can result in people not fully understanding their condition or how to manage it. By involving people in their treatment, personalised care planning can help to overcome these challenges and to develop the skills and confidence they need to manage their condition effectively.
3. Emotional support. Diabetes can have a significant impact on emotional well-being. It may be difficult to provide emotional support to individuals owing to time constraints or a lack of training in this area. Individuals may feel isolated or unsupported, which can impact their ability to manage their condition effectively. Through a more personalised approach that is built around each individual’s aims and ability, personalised care planning can help make individuals feel more supported.
4. Cultural considerations. Working with individuals from diverse cultural backgrounds can present unique challenges. Cultural beliefs and practices may impact individuals’ understanding and management of their condition, and DSNs may require additional training or resources to provide culturally competent care. The use of personalised care planning incorporates cultural and ethnic needs for each individual, ensuring their care plan is well suited to them and that they are encouraged to engage with it.
These challenges support the need for a scalable way to provide relevant information, support and self-management tools to individuals within primary care. To address these challenges, Healum developed a Collaborative Care Planning Software and App whereby HCPs in primary care can create personalised digital plans of care and support that are shared directly through a mobile app. These plans are personalised through a collaborative conversation whereby the HCP and the individual concerned can discuss their specific health objectives, goals and actions, and what barriers they currently, or are likely to, experience in achieving these. The HCP can select resources that are personalised based on the individual’s medical, cultural and socioeconomic needs, meaning they are more relevant and are more likely to be engaged with.
The care planning software has been designed to enable multidisciplinary primary care teams to work collaboratively with individuals in empowering them to identify their health concerns and objectives. The care plan format was designed to follow national guidelines, and includes a time-saving feature where goals, actions and resources auto-populate based on the goal category and preselected goals chosen. Through an integrated care and support plan, individuals are presented with a set of personally relevant, medically and socially prescribed choices that they can access anywhere and at any time, and that is tailored to their unique needs. The software is designed to be fast and easy to use to save HCP time by speeding up the process of care planning and sharing educational content to individuals. In this way, it assists the recommended standard care, without increasing the workload. Staff can, therefore, help individuals feel supported in between their appointments, without feeling an additional burden themselves.
The mobile app has been designed to improve health outcomes, quality of life (QoL) and experience of care for people with type 2 diabetes. To achieve this, individuals are supported to manage their health by providing relevant information and self-management tools that are proven to improve understanding, self-management capability, health and QoL, such as healthy behaviour change advice and the means to set goals, plan actions and track health metrics (Heald et al, 2023b).
The app includes a library of resources, including articles, videos, recipes and local services, which individuals are able to view. They can also view within the app those that have been sent to them from their HCP. To achieve better experience of care, the app was designed to improve the personalisation and quality of care to people with one or more long-term conditions, to enhance the efficiency of care and support delivery, and to improve access to support.
To test this solution, the authors designed a randomised controlled trial to evaluate the effectiveness of the Healum Collaborative Care Planning Software and App in improving health outcomes, QoL measures and engagement levels amongst individuals with type 2 diabetes. The primary outcomes measured were improvements in HbA1c and BMI over a six-month period, while the secondary outcome measured self-rated QoL based on the capability, opportunity and motivation to change behaviour.
The study recruited 197 participants, aged between 22 and 85 years, across 13 surgeries in the UK. Although the study did not code for ethnicity, the populations from which the participants were taken are predominantly White.
The intervention group received a digital care plan created with their HCP as well as the Healum app, whereas the control group received only usual care. Ahead of the recruitment of trial participants, the HCPs involved took part in a one-hour training session conducted either virtually or face-to-face. They were guided through use of the software and how individuals can use the app. Individuals who were provided with app access were guided through its functions by their HCP in the care plan appointment, as well as being provided with a user guide and demonstration videos to learn more.
The study results show that the use of this app led to statistically significant improvements in HbA1c and in QoL measures. Over 6 months, the active treatment group showed a clinically relevant drop in their HbA1c of 5.3 mmol/mol (0.6%) on average. In the control group, however, there was a slight average increase in HbA1c of 0.2 mmol/mol (0.02%). The average reduction in BMI in the treatment group was −0.7% compared to −0.2% for the control group. Interestingly, improvements in glucose control occurred in many people without reduction in BMI. The authors suggest that the app’s personalised care planning feature, which enables individuals to co-create care and support plans with healthcare professionals, contributed to these improvements by increasing individuals’ engagement in their care as well as increasing education.
To assess health-related QoL, participants were asked to complete an online survey, which included the NICE-validated EQ-5D-5L questionnaire, at the start of the trial and after 6 months. Surveys from 12 participants in each group were matched. EQ-5D-5L score (a generic measure of health status) in the intervention group increased by an average of 0.0464, whereas it decreased by 0.0086 in the control group. The EQ-VAS score (a self-rated global assessment of health) increased by an average 8.2% in the intervention group, while there was a decrease of 2.79% in the control group. The authors suggest that QoL was improved for the individuals receiving the intervention through increased support, and greater engagement and motivation.
This solution has the potential to aid diabetes nurses and the care they provide by optimising the limited time and resources they have available, increasing education of individuals with type 2 diabetes and providing emotional support, all whilst taking into consideration each individual’s cultural background. The key uses of the software and app for HCPs are: creating a care plan after an annual review that is shared through the app on the things that matter to each individual; sharing trusted information about managing health and the services that can help each individual; reviewing how an individual is getting on in between appointments in terms of medical and non-medical markers, resources viewed, services used and overall engagement. The cost of this software and app is priced at roughly £0.25 per patient per year within a practice or PCN after original EMIS set-up costs.
Although there are many self-management and condition-management platforms, Healum is based on behaviour-change science, and promotes lifestyle interventions that are personalised to a person’s comorbidities and that are recommended by their multi-disciplinary team of health and social care professionals who know the health challenges and journey of that individual. A key differentiating factor between this solution and other software/apps is the ability to print out the personalised care plans created for individuals to reduce digital inequality.
The authors concluded that the Healum Collaborative Care Planning Software and App can be an effective tool for improving health outcomes amongst individuals with type 2 diabetes through the delivery of personalised plans of care, support and accessible education. In addition, personalised care planning can help diabetes specialist nurses in primary care to address the unique needs of each individual, improve outcomes and facilitate self-management. By doing so, personalised care planning can help to overcome some of the main issues faced by primary care.
This trial demonstrates the potential for digital health solutions to increase access and self-management support for individuals with type 2 diabetes and, potentially, other long-term conditions. Follow-up the participants in relation to their longer-term outcomes continues.

Contact Us

Talk to Us

Journal of Diabetes Nursing Publication

<h3 class="heading-title">Enhancing type 2 diabetes treatment through digital plans of care. Patterns of access to a care-planning app over the first 3 months of a digital health intervention</h3>
Read the full paper <a style="color: #f68025;" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10082235/">here.</a>
&nbsp;
The increasing digitalization of healthcare brings opportunities to enable much greater patient access to evidence-based interventions [<a class=" bibr popnode" role="button" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10082235/#R1" aria-expanded="false" aria-haspopup="true">1</a>,<a class=" bibr popnode" role="button" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10082235/#R2" aria-expanded="false" aria-haspopup="true">2</a>]. A key question is the degree to which patients with long-term conditions such as type 2 diabetes (T2DM) will access an app that supports them in day-to-day management.
We recently investigated how a personalized care-planning software and patient-facing mobile app may aid people to manage their diabetes more effectively [<a class=" bibr popnode" role="button" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10082235/#R3" aria-expanded="false" aria-haspopup="true">3</a>].
People with T2DM with glycosylated haemoglobin greater than 58 mmol/mol (7.5%) were randomized (randomized controlled trial) to either the active intervention group (usual care + app) or the control group (usual care). The intervention group received a co-created personalized care plan involving daily lifestyle prompts and access to a range of resources. Randomization did not influence other decisions about diabetes management [<a class=" bibr popnode" role="button" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10082235/#R3" aria-expanded="false" aria-haspopup="true">3</a>,<a class=" bibr popnode" role="button" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10082235/#R4" aria-expanded="false" aria-haspopup="true">4</a>].
The participant age range was 19×85 years. The mean age of the T2DM participants was 63.2 years. Out of a total of 203 participants, 118 (58%) were male, 68 (33.5%) were female and 17 (8.5%) did not report their sex. The treatment group (app + usual care) and control (usual care) groups constituted 114 and 89 participants respectively.
Analysis of access to the app indicated that 30% of users used the app at least 10 times in the first month of app access, dropping to 20% in the second month. Of those accessing ≥10 times in the first month, one-third of them also used it ≥10 times in the following month and 81% used it more than twice; 84% of participants accessed the app at least twice in the first month after enrolment in the study.
In the first month, the average total number of sessions was 8.06 sessions, and the average total time spent in the app was 36.60 min. App usage in the first 3 months is shown in Fig. <a class="fig-table-link figpopup" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10082235/figure/F1/" target="figure" rel="noopener">​Fig.1a:1</a>a: average time spent in the app/month over the 3 months following activation (point of recruitment) and Fig. <a class="fig-table-link figpopup" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10082235/figure/F1/" target="figure" rel="noopener">​Fig.1b1</a>b shows the average app usage/ month in the 3 months after activation in terms of session number and average duration of sessions.
The length of time patients within the trial had been living with T2DM was between 1 and 42 years. Usage was highest in the group of app users who had been diagnosed with T2DM 11–20 years previously, spending an average total time of 54.5 min in the app in month 1 after download. There was no significant variation in app usage by sex. All users used the app in the first month following enrolment in the study (if in the intervention group arm); 47.6% used it in the second month and 31.4% used it in the third month.
Engagement with different functions within the app led to higher usage, including resources/tracking. Users who viewed between 51 and 60 resources spent 80.9 min within the app in the first month after activation, whereas users who only viewed 0–10 resources spent 19.2 min. This was also the case for app users using the tracking function within the app: specifically, the more times a user tracked something, the higher the total time they spent in the app in the first month (r2 = 0.85).
The age group who used the app the most were those aged 61–70 years old, (average total number of app sessions for these individuals over the 3-month trial = 15), the average total time spent within the app in the first month being 47.7 min. Although the average time spent within the app in the first month was lower for those patients aged 41–50 years old (15.3 min), their app usage diminished less over time.
In relation to the fact that users accessed the app less over time, it has been shown that medical apps have a 90-day retention of 34% and annual retention of 16% [<a class=" bibr popnode" role="button" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10082235/#R5" aria-expanded="false" aria-haspopup="true">5</a>].
It was found in 2020 that 65% of those over 65 are using smartphones, an increase of 26% since 2016. While more people are using smartphones, those over 65 are still the least likely age group to have a smartphone [<a class=" bibr popnode" role="button" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10082235/#R6" aria-expanded="false" aria-haspopup="true">6</a>]. It is also relevant to state that retrospective studies in T1DM have identified increasing age as a potential correlate of poorer engagement with diabetes technologies and worse outcomes [<a class=" bibr popnode" role="button" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10082235/#R7" aria-expanded="false" aria-haspopup="true">7</a>].
The relation between app usage and age/duration of diabetes provides essential insights to improve content [<a class=" bibr popnode" role="button" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10082235/#R4" aria-expanded="false" aria-haspopup="true">4</a>], so as to enhance the usage of digital support technology for diabetes/other long-term conditions, as well detailed evaluation of the patient experience. Any improvement in blood, glucose control, if sustained will have the potential to reduce cardiovascular event rate and cardiovascular mortality rate in the long term in people with T2DM [<a class=" bibr popnode" role="button" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10082235/#R8" aria-expanded="false" aria-haspopup="true">8</a>].
<div id="R1" class="ref-cit-blk half_rhythm">References:</div>
<div class="ref-cit-blk half_rhythm">1. Velardo C, Shah SA, Gibson O, Clifford G, Heneghan C, Rutter H, et al..; EDGE COPD Team. Digital health system for personalised COPD long-term management. BMC Med Inform Decis Mak 2017; 17:19. [<a class="int-reflink" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5319140/">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28219430">PubMed</a>] [<a role="button" href="https://scholar.google.com/scholar_lookup?journal=BMC+Med+Inform+Decis+Mak&amp;title=Digital+health+system+for+personalised+COPD+long-term+management.&amp;author=C+Velardo&amp;author=SA+Shah&amp;author=O+Gibson&amp;author=G+Clifford&amp;author=C+Heneghan&amp;volume=17&amp;publication_year=2017&amp;pages=19&amp;pmid=28219430&amp;" target="_blank" rel="noopener noreferrer" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</div>
<div id="R2" class="ref-cit-blk half_rhythm">2. Foley P, Steinberg D, Levine E, Askew S, Batch BC, Puleo EM, et al.. Track: a randomized controlled trial of a digital health obesity treatment intervention for medically vulnerable primary care patients. Contemp Clin Trials 2016; 48:12–20. [<a class="int-reflink" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4885789/">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26995281">PubMed</a>] [<a role="button" href="https://scholar.google.com/scholar_lookup?journal=Contemp+Clin+Trials&amp;title=Track:+a+randomized+controlled+trial+of+a+digital+health+obesity+treatment+intervention+for+medically+vulnerable+primary+care+patients.&amp;author=P+Foley&amp;author=D+Steinberg&amp;author=E+Levine&amp;author=S+Askew&amp;author=BC+Batch&amp;volume=48&amp;publication_year=2016&amp;pages=12-20&amp;pmid=26995281&amp;" target="_blank" rel="noopener noreferrer" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</div>
<div id="R3" class="ref-cit-blk half_rhythm">3. Heald AH, Gimeno LA, Gilingham E, Hudson L, Price L, Saboo A, et al.. Enhancing type 2 diabetes treatment through digital plans of care. First results from the East Cheshire Study of an app to support people in the management of type 2 diabetes. Cardiovasc Endocrinol Metab 2022; 11:e0268. [<a class="int-reflink" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9298469/">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35923172">PubMed</a>] [<a role="button" href="https://scholar.google.com/scholar_lookup?journal=Cardiovasc+Endocrinol+Metab&amp;title=Enhancing+type+2+diabetes+treatment+through+digital+plans+of+care.+First+results+from+the+East+Cheshire+Study+of+an+app+to+support+people+in+the+management+of+type+2+diabetes.&amp;author=AH+Heald&amp;author=LA+Gimeno&amp;author=E+Gilingham&amp;author=L+Hudson&amp;author=L+Price&amp;volume=11&amp;publication_year=2022&amp;pages=e0268&amp;pmid=35923172&amp;" target="_blank" rel="noopener noreferrer" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</div>
<div id="R4" class="ref-cit-blk half_rhythm">4. Zimmermann G, Venkatesan A, Rawlings K, Scahill MD. Improved glycemic control with a digital health intervention in adults with type 2 diabetes: retrospective study. JMIR Diabetes 2021; 6:e28033. [<a class="int-reflink" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8209528/">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34075880">PubMed</a>] [<a role="button" href="https://scholar.google.com/scholar_lookup?journal=JMIR+Diabetes&amp;title=Improved+glycemic+control+with+a+digital+health+intervention+in+adults+with+type+2+diabetes:+retrospective+study.&amp;author=G+Zimmermann&amp;author=A+Venkatesan&amp;author=K+Rawlings&amp;author=MD+Scahill&amp;volume=6&amp;publication_year=2021&amp;pages=e28033&amp;pmid=34075880&amp;" target="_blank" rel="noopener noreferrer" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</div>
<div id="R5" class="ref-cit-blk half_rhythm">5. <a href="https://www.apptentive.com/blog/healthcare-apps-2021-engagement-benchmarks/" target="_blank" rel="noopener" data-ga-action="click_feat_suppl">https://www.apptentive.com/blog/healthcare-apps-2021-engagement-benchmarks/</a>. [Accessed 24 February 2023].</div>
<div id="R6" class="ref-cit-blk half_rhythm">6. <a href="https://www.ageco.co.uk/useful-articles/money/the-best-mobile-phones-for-the-elderly/#:~:text=It%20was%20found%20in%202020,have%20grown%20up%20using%20them" target="_blank" rel="noopener" data-ga-action="click_feat_suppl">https://www.ageco.co.uk/useful-articles/money/the-best-mobile-phones-for-the-elderly/#:~:text=It%20was%20found%20in%202020,have%20grown%20up%20using%20them</a>. [Accessed 1 March 2023].</div>
<div id="R7" class="ref-cit-blk half_rhythm">7. McCarthy MM, Grey M. Type 1 diabetes self-management from emerging adulthood through older adulthood. Diabetes Care 2018; 41:1608–1614. [<a href="https://pubmed.ncbi.nlm.nih.gov/29802144">PubMed</a>] [<a role="button" href="https://scholar.google.com/scholar_lookup?journal=Diabetes+Care&amp;title=Type+1+diabetes+self-management+from+emerging+adulthood+through+older+adulthood.&amp;author=MM+McCarthy&amp;author=M+Grey&amp;volume=41&amp;publication_year=2018&amp;pages=1608-1614&amp;pmid=29802144&amp;" target="_blank" rel="noopener noreferrer" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</div>
<div id="R8" class="ref-cit-blk half_rhythm">8. Laiteerapong N, Ham SA, Gao Y, Moffet HH, Liu JY, Huang ES, et al.. The legacy effect in type 2 diabetes: impact of early glycemic control on future complications (the diabetes &amp; aging study). Diabetes Care 2019; 42:416–426. [<a class="int-reflink" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6385699/">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30104301">PubMed</a>] [<a role="button" href="https://scholar.google.com/scholar_lookup?journal=Diabetes+Care&amp;title=The+legacy+effect+in+type+2+diabetes:+impact+of+early+glycemic+control+on+future+complications+(the+diabetes+&amp;+aging+study).&amp;author=N+Laiteerapong&amp;author=SA+Ham&amp;author=Y+Gao&amp;author=HH+Moffet&amp;author=JY+Liu&amp;volume=42&amp;publication_year=2019&amp;pages=416-426&amp;pmid=30104301&amp;" target="_blank" rel="noopener noreferrer" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</div>
<div class="c-article-table-container">
<div class="c-article-table-border c-table-scroll-wrapper">
<div class="c-table-scroll-wrapper__content c-table-scroll-wrapper__fade--transparent" data-component-scroll-wrapper=""></div>
</div>
</div>

Cardiovascular Endocrinology and Metabolism Journal Publication

<h3 class="c-article-title c-article-title--long" data-test="article-title">A Randomised Control Trial to Explore the Impact and Efficacy of the Healum Collaborative Care Planning Software and App on Condition Management in the Type 2 Diabetes Mellitus Population in NHS Primary Care</h3>
Read the full paper <a style="color: #f68025;" href="https://link.springer.com/article/10.1007/s13300-023-01404-6">here.</a>
&nbsp;
<h2 id="Abs1" class="c-article-section__title js-section-title js-c-reading-companion-sections-item">Abstract</h2>
<div id="Abs1-content" class="c-article-section__content">
<h3 class="c-article__sub-heading" data-test="abstract-sub-heading">Introduction</h3>
Effective and scalable solutions to support management of Type 2 Diabetes (T2D) at a distance are a priority for health systems worldwide. The use of personalised care planning has been shown to be effective at improving the health outcomes and the experience of care amongst people with T2D and other long-term health conditions. Here we describe a specific example of such an intervention.
<h3 class="c-article__sub-heading" data-test="abstract-sub-heading">Methods</h3>
The sample comprised 197 participants with T2D randomised to either the active intervention group with digital health planning (App + usual care), with 115 participants, or the control group (usual care), with 82 participants. We analysed data in relation to changes in body mass index (BMI) and glycated haemoglobin (HbA1c) over a 6-month follow-up period. We also analysed responses to questionnaires sent out and held interviews with participants that were in the active treatment group and therefore had a care plan created and access to an app.
<h3 class="c-article__sub-heading" data-test="abstract-sub-heading">Results</h3>
The active treatment group had significant reductions in HbA1c (p &lt; 0.01) and BMI (p &lt; 0.037) vs the control group (no significant change). The average percentage change in HbA1c for the treatment group over 6 months was − 7.4% (± SE 1.4%), compared with 1.8% (± SE 2.1%) for the control group. The average percentage change in BMI for the treatment group was − 0.7% (± SE 0.4%) and it was − 0.2% (± SE 0.5%) for the control group. A higher percentage of the active treatment group reduced their HbA1c and BMI than the control group. For HbA1c, 72.4% of the active treatment group reduced their HbA1c, compared to 41.5% of the control group. For BMI, 52.7% of the active treatment group experienced a reduction, compared to 42.9% for the control group. Self-measured quality of life (QoL) improved for patients in the active treatment group, shown by an increase in their pre-trial to post-trial EQ-5D-5L rating by an average of 0.0464 (± SE 0.0625), compared to a decrease of 0.0086 (± SE 0.0530) for the control group. The average EQ VAS score also increased pre- to post-trial for the active treatment group, on average by 8.2%, whereas it decreased by an  average of − 2.8% for the control group.
<h3 class="c-article__sub-heading" data-test="abstract-sub-heading">Conclusion</h3>
These findings point to how the provision of personalised plans of care, support and education linked to a mobile app, can result in HbA1c and BMI reduction for many individuals with T2D. The use of a patient management app as well as a personalised care plan also led to an improvement in patient self-rated QoL and engagement.
</div>
Key Summary Points
<ul>
<li>The number of people with type 2 diabetes (T2D) is steadily increasing, thus there  is a need for them to self-manage more effectively to reduce the complications of this disorder and reduce the pressure within primary care of treating these patients.</li>
<li>This study set out to evaluate whether a personalised care planning software and patient-facing mobile app could improve health outcomes amongst people with T2D.</li>
<li>The provision of personalised plans of care, support and education linked to a mobile app, resulted in HbA1c and BMI reductions over a 6-month period for individuals with T2D.</li>
<li>The provision of personalised plans of care, support and education linked to a mobile app, resulted in an improvement in quality of life and patient engagement for individuals with T2D.</li>
</ul>
<div class="c-article-table-container">
<div class="c-article-table-border c-table-scroll-wrapper">
<div class="c-table-scroll-wrapper__content c-table-scroll-wrapper__fade--transparent" data-component-scroll-wrapper=""></div>
</div>
</div>

Diabetes Therapy Journal Publication

Digital solutions for personalised  proactive care for patients with Type 2 Diabetes in primary care
&nbsp;
A randomised control study to explore the impact and efficacy of the Healum Collaborative Care planning Software and App on condition management in the Type 2 Diabetes Mellitus Population in NHS Primary Care.
&nbsp;
Type 2 Diabetes in Primary Care:
The increasing number of people living with long-term conditions (LTCs) is one of the biggest challenges facing our health and social care systems. In 2019, 463 million adults globally were living with diabetes, and this number is predicted to increase to 700 million by 2045, with Type 2 Diabetes (T2D) making up 90% of this population. This high prevalence results in Type T2D costing the NHS over £14bn per year. 
&nbsp;
The Opportunity: 
Healum previously identified challenges faced in primary care of high T2D prevalence, yet poor self-management due to a gap in self-management support provided by healthcare professionals (HCPs). To address this, a need was identified for a scalable way for multidisciplinary teams within primary care to provide relevant plans of care and support to patients. Healum worked with Vernova Healthcare to evaluate the Care Planning software and accompanying patient-facing app in a real-world randomised control trial to determine the impact on lifestyle, behavioural and health outcomes for patients living with T2D. 
&nbsp;
The Solution:
The Healum solution has been designed to provide patients with co-created care and support plans to help them manage their LTC better, to ultimately improve health outcomes, access to care, and the efficiency of HCPs delivering care to patients with one or multiple LTCs. The software enables teams of HCPs within the NHS to provide personalised care as well as motivate, monitor and support patients in managing their health in a way that is personal to them at all the moments that matter in determining their health outcomes, whatever their cultural or socioeconomic background. Through a seamless integrated with EMIS Web, HCPs are able to quickly open a patient profile in Care Planning Healum, whilst extracting the necessary patient information and feeding information back into the patient record, as well as sharing information directly to the patient.
&nbsp;
Diabetes nurses and doctors involved in the trial were able to:
<ol>
<li style="font-weight: 400;" aria-level="1">set goals and actions as part of a shared decision making process with each  patient</li>
<li style="font-weight: 400;" aria-level="1">monitor patient progress and outcomes around the goals and intentions they had set</li>
<li style="font-weight: 400;" aria-level="1">share relevant resources and services that support patients to adopt healthy lifestyle choices</li>
<li style="font-weight: 400;" aria-level="1">automatically update patients with their most recent test results from EMIS </li>
</ol>
&nbsp;
The Key Outcomes:
&nbsp;
Patients that used the Healum app reduced their HbA1c and BMI
The average percentage change in HbA1c for the treatment group over 6 months was -7.37% (±se 1.40%), but +1.75% (±se 2.05%) for the control group, and for BMI  was -0.66% (±se 0.42%) for active treatment and -0.23% (±se 0.52%) for the control group. 72.41% of the active treatment group reduced their HbA1c, compared to just 41.54% of the control group. For BMI, 55.41% of the active treatment group had a reduction, compared to 50% for the control group.
&nbsp;
Patients that used the Healum app saw an improvement in quality of life (QoL)
Patients with app access had improvements in both EQ5D5L and EQ VAS, two measures of self-rated QoL. Patients with a care plan and app had an average change in their pre- to post-trial EQ5D5L score of 0.0464, compared to -0.0086 for patients’ without the app, and an average change in their pre- to post-trial EQ VAS score of 8.2%, compared to -2.8% for those without the app. 
&nbsp;
Patients had a better care experience from additional support through the app
The popularity and value of the app in providing support is shown by users completing 2,078 sessions, with 30% of users using the app at least 10 times and 84% at least twice in the first 30 days.
<img loading="lazy" decoding="async" class=" wp-image-1794 aligncenter" src="http://healum.sd-clients.com/wp-content/uploads/2023/12/Screen-Shot-2023-12-15-at-11.46.53-300x121.png" alt="" width="375" height="151" srcset="https://healum.sd-clients.com/wp-content/uploads/2023/12/Screen-Shot-2023-12-15-at-11.46.53-300x121.png 300w, https://healum.sd-clients.com/wp-content/uploads/2023/12/Screen-Shot-2023-12-15-at-11.46.53-1024x412.png 1024w, https://healum.sd-clients.com/wp-content/uploads/2023/12/Screen-Shot-2023-12-15-at-11.46.53-768x309.png 768w, https://healum.sd-clients.com/wp-content/uploads/2023/12/Screen-Shot-2023-12-15-at-11.46.53.png 1348w" sizes="auto, (max-width: 375px) 100vw, 375px" />
Multidisciplinary teams were able to better motivate and educate patients 
Across the 103 app users, 280 useful goals were agreed and shared in care plans, with a further 343 goals then joined in the app, such as “To be healthy enough to have a safe pregnancy”. Resources were shared 5,396 times and viewed over 2,200 times, including &#8220;1-minute omelette&#8221;. 
<img loading="lazy" decoding="async" class="size-medium wp-image-1793 aligncenter" src="http://healum.sd-clients.com/wp-content/uploads/2023/12/Screen-Shot-2023-12-15-at-11.46.47-300x152.png" alt="" width="300" height="152" srcset="https://healum.sd-clients.com/wp-content/uploads/2023/12/Screen-Shot-2023-12-15-at-11.46.47-300x152.png 300w, https://healum.sd-clients.com/wp-content/uploads/2023/12/Screen-Shot-2023-12-15-at-11.46.47-1024x518.png 1024w, https://healum.sd-clients.com/wp-content/uploads/2023/12/Screen-Shot-2023-12-15-at-11.46.47-768x388.png 768w, https://healum.sd-clients.com/wp-content/uploads/2023/12/Screen-Shot-2023-12-15-at-11.46.47.png 1092w" sizes="auto, (max-width: 300px) 100vw, 300px" />
Primary care staff were able to understand their patients’ needs better
Actionable insights were generated from patient monitoring, involving 6,279 healthy choices and actions undertaken by app users (average of 61 per user), a combination of over 1,000 actions completed, 343 goals joined, over 2,400 trackers used and over 2,200 resource views.
&nbsp;
Health inequalities were addressed through providing personalised care
The solution helps to address health inequalities by allowing staff to tailor the resources, goals and plans they share to each individual based on their socioeconomic or cultural backgrounds. 
<img loading="lazy" decoding="async" class="size-medium wp-image-1792 aligncenter" src="http://healum.sd-clients.com/wp-content/uploads/2023/12/Screen-Shot-2023-12-15-at-11.46.39-300x147.png" alt="" width="300" height="147" srcset="https://healum.sd-clients.com/wp-content/uploads/2023/12/Screen-Shot-2023-12-15-at-11.46.39-300x147.png 300w, https://healum.sd-clients.com/wp-content/uploads/2023/12/Screen-Shot-2023-12-15-at-11.46.39-1024x502.png 1024w, https://healum.sd-clients.com/wp-content/uploads/2023/12/Screen-Shot-2023-12-15-at-11.46.39-768x376.png 768w, https://healum.sd-clients.com/wp-content/uploads/2023/12/Screen-Shot-2023-12-15-at-11.46.39.png 1098w" sizes="auto, (max-width: 300px) 100vw, 300px" />

Contact us for a demo

RCT for Diabetes management in primary care

<h2></h2>
<h2 class="qodef-post-title">Launch of India subsidiary: Healum India Private Ltd</h2>
<h3>We founded Healum in late 2014 with a mission to extend the lives and improve the quality of life for hundreds of millions of people through digital solutions that enable health professionals to provide proactive personalised healthcare to people with long-term conditions, whether that be remotely or in person.</h3>
During the past 8 years we have worked hard in the UK to deliver our health technology platform for healthcare providers in the private sector and public sector so that they can empower people with one or more long term conditions to make the right choices at the moments that matter in their daily lives. Healum’s digital solutions now enable healthcare providers to improve health outcomes, access to care, and the efficiency of delivering care to patients with one or more long term conditions. 
&nbsp;
&nbsp;
 Our journey has been a long and fulfilling one, and we are grateful for all of the backing and support that we have received from patients, healthcare professionals and commissioning organisations to fund, develop and test our technology within the NHS. The UK is an incredible country to develop, implement and evaluate health technology for the following reasons: 
&nbsp;
<ul>
<li>The NHS has a clear strategy and plan for using digital technology and data to save and improve lives.</li>
<li>NHS England’s Transformation Directorate created the Digital Technology Assessment Criteria for health and social care (DTAC) which set centralised standards for anyone developing digital solutions.</li>
<li>National Institute for Clinical Excellence (NICE) has a clear framework for evidence standards for digital solutions which provides clarity around the research that needs to be done.</li>
<li>National Institute for Health Research provides hands-on support for companies like us to fund and develop our research roadmap.</li>
<li>The Accelerated Access Collaborative provides more support than one could possibly imagine to get innovations into the hands of clinicians and patients faster whilst encouraging innovation in the NHS.</li>
<li>UK Research and Innovation (UKRI) is an incredible organisation that supports the commercialisation, development and funding of innovative health technology.  </li>
<li>The Department of International Trade and its tireless digital health team are ambassadors for bringing the best of UK healthtech to the world and do a wonderful job in supporting small companies like us to work with international partners.</li>
</ul>
&nbsp;
&nbsp;
 We are grateful to all of these organisations for the faith that they have placed in Healum in giving us the opportunity to serve the public, and for their hands-on support and guidance in helping us to fund, develop, implement and evaluate Healum’s products in aiding healthcare professionals to empower people with multiple long term conditions to manage their health. These organisations raise the quality of digital health companies in the UK and set us all up to work with Life Science companies, Healthcare providers, and their patient populations in other parts of the world.
&nbsp;
&nbsp;
<div class="wp-block-image is-style-default">
<figure class="aligncenter size-large is-resized"><img loading="lazy" decoding="async" class="alignnone size-medium wp-image-1575" src="http://healum.sd-clients.com/wp-content/uploads/2023/10/jonanuj-300x200.jpeg" alt="" width="300" height="200" srcset="https://healum.sd-clients.com/wp-content/uploads/2023/10/jonanuj-300x200.jpeg 300w, https://healum.sd-clients.com/wp-content/uploads/2023/10/jonanuj-768x512.jpeg 768w, https://healum.sd-clients.com/wp-content/uploads/2023/10/jonanuj.jpeg 1024w" sizes="auto, (max-width: 300px) 100vw, 300px" /> 
<figcaption class="wp-element-caption">Anuj and Jon, Healum’s cofounders</figcaption>
</figure>
</div>
&nbsp;
&nbsp;
 It therefore gives us great pleasure this week as Diwali celebrations come to a close and as the first person of South Asian origin becomes UK Prime Minister, to announce that our India subsidiary, trading as Healum India Pvt Ltd, is now open for business. With a $21bn healthcare market projected for 2025, with 77 million people suffering from Type 2 Diabetes and with obesity affecting 5% of its 1.38 billion population, India is a natural place for Healum to launch the first phase of its international expansion efforts in its mission to provide proactive personalised healthcare for all. As a market it is a vibrant one, with India’s preventive healthcare sector – fitness, wellness, foods and supplements, early diagnostics and health tracking – projected to reach $197 bn by 2025, growing at a CAGR of 22%, said a recent report by Consulting firm Redseer Strategy Consultants in collaboration with Chiratae Ventures and Amazon Web Services.
&nbsp;
&nbsp;
&nbsp;
&nbsp;
&nbsp;
<div class="wp-block-image">
<figure class="aligncenter size-medium"><img loading="lazy" decoding="async" class="alignnone size-medium wp-image-1576" src="http://healum.sd-clients.com/wp-content/uploads/2023/10/india-pop-251x300.png" alt="" width="251" height="300" srcset="https://healum.sd-clients.com/wp-content/uploads/2023/10/india-pop-251x300.png 251w, https://healum.sd-clients.com/wp-content/uploads/2023/10/india-pop.png 384w" sizes="auto, (max-width: 251px) 100vw, 251px" /> 
<figcaption class="wp-element-caption">The trend in India’s population growth estimates the population will overtake China’s. Source: UN</figcaption>
</figure>
</div>
&nbsp;
 Our international growth strategy was devised and developed as part of a UKRI-funded project, under the Digital Health Technology Catalyst (DHTC) programme, part of the Medicines Manufacturing Challenge, which enabled the company to develop the machine learning algorithms that power recommendations in its patient management system. 
&nbsp;
&nbsp;
 Since founding the company back in 2014 we have a track record of working with many talented healthcare professionals, developers and investors in India who have been part of Healum’s origins. The people in our company have strong family and business connections in India. Anuj Saboo our CTO and Cofounder grew up in Mumbai dreaming of building AI assistive technology, inspired by his love of the talking car Kit from the 1980s TV programme ‘Knight Rider’. After graduating with a degree in Computer Science from Mumbai he pursued his postgraduate studies in the UK and pursued a successful career in Technology. Jonathan Abraham, our CEO and Cofounder, has strong family ties with India. His father and his grandparents grew up in Kolkata, and Indian culture played a significant part in his own upbringing.  In 2018, Healum was fortunate to be backed by a set of Angel Investors in India that saw our vision for delivering proactive personalised healthcare. In addition to this, Healum has worked with many talented developers and designers in building and rolling out its digital health platform these past years.
<blockquote class="wp-block-quote">
“In many ways our incorporation and launch of Healum India feels more like the company coming home rather than an expansion into a new market. When you work with a team of developers, designers and project managers from a country, it is inevitable that their shared experiences and cultural identity makes its way into your product offering.”
<cite>Anuj Saboo, Healum’s CTO and Cofounder</cite></blockquote>
At Healum we are now excited to be working with the Department of International Trade to connect with partners across India that can help make our vision of proactive personalised care for all people a reality.  With the share of private consumption expenditure on health growing at a compound annual growth rate (CAGR) of 16.4%, Healums technology will be of use to both people in India who are spending more on personalised healthcare, with health conscious individuals spending between Rs 4000 to Rs 10,000 on preventive health, and in providing remote access to healthcare for 700 million people in underserved rural populations where there is only an estimated 60% of coverage. Healum’s cloud-based interoperable software will enable teams of healthcare professionals in India to offer remote services to their patients and will enable Life Science companies to offer digital therapeutics that support patients to manage their health.  
&nbsp;
&nbsp;
 At Healum we are also encouraged by the vision and commitment from India’s investment community to invest in the health technologies of the future, with healthtech funding in India standing at $2.2bn in 2021 and set to grow in 2022, and with over 40 preventative healthcare startups raising $1bn in funding in 2022.
&nbsp;
&nbsp;
The company is now looking for investors, healthcare providers and life science partners that are interested in working with Healum, to scale the adoption of its digital technology and services across India.
&nbsp;
 If you are a healthcare provider or life-science company in India and wish to partner with Healum to deliver digital services to patients then get in touch at <a href="mailto:hello@healum.com">hello@healum.com</a>.
&nbsp;
<h2></h2>
<h2 class="qodef-post-title">Launch of India subsidiary: Healum India Private Ltd</h2>
<h3>We founded Healum in late 2014 with a mission to extend the lives and improve the quality of life for hundreds of millions of people through digital solutions that enable health professionals to provide proactive personalised healthcare to people with long-term conditions, whether that be remotely or in person.</h3>
During the past 8 years we have worked hard in the UK to deliver our health technology platform for healthcare providers in the private sector and public sector so that they can empower people with one or more long term conditions to make the right choices at the moments that matter in their daily lives. Healum’s digital solutions now enable healthcare providers to improve health outcomes, access to care, and the efficiency of delivering care to patients with one or more long term conditions. 
&nbsp;
&nbsp;
 Our journey has been a long and fulfilling one, and we are grateful for all of the backing and support that we have received from patients, healthcare professionals and commissioning organisations to fund, develop and test our technology within the NHS. The UK is an incredible country to develop, implement and evaluate health technology for the following reasons: 
&nbsp;
<ul>
<li>The NHS has a clear strategy and plan for using digital technology and data to save and improve lives.</li>
<li>NHS England’s Transformation Directorate created the Digital Technology Assessment Criteria for health and social care (DTAC) which set centralised standards for anyone developing digital solutions.</li>
<li>National Institute for Clinical Excellence (NICE) has a clear framework for evidence standards for digital solutions which provides clarity around the research that needs to be done.</li>
<li>National Institute for Health Research provides hands-on support for companies like us to fund and develop our research roadmap.</li>
<li>The Accelerated Access Collaborative provides more support than one could possibly imagine to get innovations into the hands of clinicians and patients faster whilst encouraging innovation in the NHS.</li>
<li>UK Research and Innovation (UKRI) is an incredible organisation that supports the commercialisation, development and funding of innovative health technology.  </li>
<li>The Department of International Trade and its tireless digital health team are ambassadors for bringing the best of UK healthtech to the world and do a wonderful job in supporting small companies like us to work with international partners.</li>
</ul>
&nbsp;
&nbsp;
 We are grateful to all of these organisations for the faith that they have placed in Healum in giving us the opportunity to serve the public, and for their hands-on support and guidance in helping us to fund, develop, implement and evaluate Healum’s products in aiding healthcare professionals to empower people with multiple long term conditions to manage their health. These organisations raise the quality of digital health companies in the UK and set us all up to work with Life Science companies, Healthcare providers, and their patient populations in other parts of the world.
&nbsp;
&nbsp;
<div class="wp-block-image is-style-default">
<figure class="aligncenter size-large is-resized"><img loading="lazy" decoding="async" class="alignnone size-medium wp-image-1575" src="http://healum.sd-clients.com/wp-content/uploads/2023/10/jonanuj-300x200.jpeg" alt="" width="300" height="200" srcset="https://healum.sd-clients.com/wp-content/uploads/2023/10/jonanuj-300x200.jpeg 300w, https://healum.sd-clients.com/wp-content/uploads/2023/10/jonanuj-768x512.jpeg 768w, https://healum.sd-clients.com/wp-content/uploads/2023/10/jonanuj.jpeg 1024w" sizes="auto, (max-width: 300px) 100vw, 300px" /> 
<figcaption class="wp-element-caption">Anuj and Jon, Healum’s cofounders</figcaption>
</figure>
</div>
&nbsp;
&nbsp;
 It therefore gives us great pleasure this week as Diwali celebrations come to a close and as the first person of South Asian origin becomes UK Prime Minister, to announce that our India subsidiary, trading as Healum India Pvt Ltd, is now open for business. With a $21bn healthcare market projected for 2025, with 77 million people suffering from Type 2 Diabetes and with obesity affecting 5% of its 1.38 billion population, India is a natural place for Healum to launch the first phase of its international expansion efforts in its mission to provide proactive personalised healthcare for all. As a market it is a vibrant one, with India’s preventive healthcare sector – fitness, wellness, foods and supplements, early diagnostics and health tracking – projected to reach $197 bn by 2025, growing at a CAGR of 22%, said a recent report by Consulting firm Redseer Strategy Consultants in collaboration with Chiratae Ventures and Amazon Web Services.
&nbsp;
&nbsp;
&nbsp;
&nbsp;
&nbsp;
<div class="wp-block-image">
<figure class="aligncenter size-medium"><img loading="lazy" decoding="async" class="alignnone size-medium wp-image-1576" src="http://healum.sd-clients.com/wp-content/uploads/2023/10/india-pop-251x300.png" alt="" width="251" height="300" srcset="https://healum.sd-clients.com/wp-content/uploads/2023/10/india-pop-251x300.png 251w, https://healum.sd-clients.com/wp-content/uploads/2023/10/india-pop.png 384w" sizes="auto, (max-width: 251px) 100vw, 251px" /> 
<figcaption class="wp-element-caption">The trend in India’s population growth estimates the population will overtake China’s. Source: UN</figcaption>
</figure>
</div>
&nbsp;
 Our international growth strategy was devised and developed as part of a UKRI-funded project, under the Digital Health Technology Catalyst (DHTC) programme, part of the Medicines Manufacturing Challenge, which enabled the company to develop the machine learning algorithms that power recommendations in its patient management system. 
&nbsp;
&nbsp;
 Since founding the company back in 2014 we have a track record of working with many talented healthcare professionals, developers and investors in India who have been part of Healum’s origins. The people in our company have strong family and business connections in India. Anuj Saboo our CTO and Cofounder grew up in Mumbai dreaming of building AI assistive technology, inspired by his love of the talking car Kit from the 1980s TV programme ‘Knight Rider’. After graduating with a degree in Computer Science from Mumbai he pursued his postgraduate studies in the UK and pursued a successful career in Technology. Jonathan Abraham, our CEO and Cofounder, has strong family ties with India. His father and his grandparents grew up in Kolkata, and Indian culture played a significant part in his own upbringing.  In 2018, Healum was fortunate to be backed by a set of Angel Investors in India that saw our vision for delivering proactive personalised healthcare. In addition to this, Healum has worked with many talented developers and designers in building and rolling out its digital health platform these past years.
<blockquote class="wp-block-quote">
“In many ways our incorporation and launch of Healum India feels more like the company coming home rather than an expansion into a new market. When you work with a team of developers, designers and project managers from a country, it is inevitable that their shared experiences and cultural identity makes its way into your product offering.”
<cite>Anuj Saboo, Healum’s CTO and Cofounder</cite></blockquote>
At Healum we are now excited to be working with the Department of International Trade to connect with partners across India that can help make our vision of proactive personalised care for all people a reality.  With the share of private consumption expenditure on health growing at a compound annual growth rate (CAGR) of 16.4%, Healums technology will be of use to both people in India who are spending more on personalised healthcare, with health conscious individuals spending between Rs 4000 to Rs 10,000 on preventive health, and in providing remote access to healthcare for 700 million people in underserved rural populations where there is only an estimated 60% of coverage. Healum’s cloud-based interoperable software will enable teams of healthcare professionals in India to offer remote services to their patients and will enable Life Science companies to offer digital therapeutics that support patients to manage their health.  
&nbsp;
&nbsp;
 At Healum we are also encouraged by the vision and commitment from India’s investment community to invest in the health technologies of the future, with healthtech funding in India standing at $2.2bn in 2021 and set to grow in 2022, and with over 40 preventative healthcare startups raising $1bn in funding in 2022.
&nbsp;
&nbsp;
The company is now looking for investors, healthcare providers and life science partners that are interested in working with Healum, to scale the adoption of its digital technology and services across India.
&nbsp;
 If you are a healthcare provider or life-science company in India and wish to partner with Healum to deliver digital services to patients then get in touch at <a href="mailto:hello@healum.com">hello@healum.com</a>.
&nbsp;

Launch of India subsidiary: Healum India Private Ltd

<h2></h2>
<h2 class="qodef-post-title">Healum wins NHS contract for patients at risk of CVD</h2>
<h3>Healum wins NHS contract to scale the use of its integrated care planning software and patient facing self-management app to support patients at risk of CVD.</h3>
 Cardiovascular disease (CVD) is the single biggest condition where lives can be saved by the NHS over the next decade. There are 7.6 million people living with CVD in the UK, and Cardiovascular Disease is a leading cause of premature disability, mortality, and health inequalities, and is responsible for one in four deaths each year (British Heart Foundation). The UK Health Security Agency estimates that the annual healthcare costs in England relating to CVD are around £7.4 billion, with an annual cost to the wider economy of £15.8 billion.
&nbsp;
 Healum has been awarded a significant contract by the NHS to scale the use of its integrated care planning software and patient facing self-management app to support multidisciplinary teams of healthcare professionals working in primary care to implement personalised care and support strategies to patients at risk of Cardiovascular disease across Cheshire and Merseyside, London, Lancashire and South Cumbria, in an area that covers 8.5 million patients.
&nbsp;
 Healthcare professionals who are using Healum’s care planning software and connected mobile app, will benefit from the ability to reduce the pressure on their workforce, empower their patients and improve health outcomes by collaboratively creating personalised care-plans with patients that are identified at risk of cardiovascular disease. The care plans are linked to the GP health record and combine clinical and non-clinical recommendations as part of a shared decision-making process that involves staff from across each practice, including GPs, nurses, pharmacists, healthcare assistants, health and wellbeing coaches and social prescribing link workers.  Patients at risk of cardiovascular disease will be able to conveniently access their personalised plan of care and support from their GP practice through a mobile app that enables them to proactively manage their health through daily actions, educational articles and videos, and information on services in their community.
&nbsp;
 The contract comes off the back of research and development carried out across Cheshire and the North West of England, carried out by Healum in partnership with Vernova CIC, supported by the National Institute for Health Research Greater Manchester team and evaluated by Dr Adrian Heald, Clinical Research Fellow at Manchester University and Consultant Endocrinologist at Salford Royal Foundation Hospital.
&nbsp;
 This contract enables Healum to expand the NHS partners in its research consortium to include Howbeck Healthcare, Lancashire and South Cumbria NHS Integrated Care Board and to increase the number of GP Practices that can access its solution. Additional support from Innovation Agency North West and Health Innovation Network will enable Healum to shape its programme of real-world testing and health economic analysis to demonstrate impact for patients, healthcare professionals and the system as a whole.
&nbsp;
 The contract has been awarded by the Accelerated Access Collaborative (AAC), which is a partnership between patient groups, government bodies, industry and the NHS hosted by NHS England, through SBRI Healthcare. It marks a renewed focus on tackling CVD through Improving current prevention strategies through use of data and personalised approaches and in empowering patients to manage their own conditions through targeted engagement and support.
&nbsp;
 The AAC has awarded a small number of contracts to the most innovative companies in the UK that can have the biggest real-world impact within the NHS system for cardiovascular disease.
&nbsp;
 Matt Whitty, CEO of the AAC, said “These awards will help the NHS to develop new technologies and solutions to address some of the biggest healthcare challenges facing society. We have selected these innovations because they have the potential to make a big difference to patients. By supporting the most promising innovations the NHS will continue to evolve, helping meet more patients’ needs and encouraging more innovators to come forward with ideas that make a difference.”
&nbsp;
 Jonathan Abraham CEO of Healum said “empowering people each day to make healthier choices through access to personalised proactive care wherever they are and whenever they need lies at the heart of our vision. This NHS contract is a validation of our evidence to date, the value of our product and its potential to impact the lives of millions of people. We look forward to working with our partners in the NHS to ease the burden on primary care and to improve outcomes for patients across the UK.”
&nbsp;
 <a href="https://sbrihealthcare.co.uk/news/the-accelerated-access-collaborative-through-sbri-healthcare-awards-3-3-million-to-accelerate-cardiovascular-disease-cvd-innovations/">Link to the full release from SBRI</a>
<h2></h2>
<h2 class="qodef-post-title">Healum wins NHS contract for patients at risk of CVD</h2>
<h3>Healum wins NHS contract to scale the use of its integrated care planning software and patient facing self-management app to support patients at risk of CVD.</h3>
 Cardiovascular disease (CVD) is the single biggest condition where lives can be saved by the NHS over the next decade. There are 7.6 million people living with CVD in the UK, and Cardiovascular Disease is a leading cause of premature disability, mortality, and health inequalities, and is responsible for one in four deaths each year (British Heart Foundation). The UK Health Security Agency estimates that the annual healthcare costs in England relating to CVD are around £7.4 billion, with an annual cost to the wider economy of £15.8 billion.
&nbsp;
 Healum has been awarded a significant contract by the NHS to scale the use of its integrated care planning software and patient facing self-management app to support multidisciplinary teams of healthcare professionals working in primary care to implement personalised care and support strategies to patients at risk of Cardiovascular disease across Cheshire and Merseyside, London, Lancashire and South Cumbria, in an area that covers 8.5 million patients.
&nbsp;
 Healthcare professionals who are using Healum’s care planning software and connected mobile app, will benefit from the ability to reduce the pressure on their workforce, empower their patients and improve health outcomes by collaboratively creating personalised care-plans with patients that are identified at risk of cardiovascular disease. The care plans are linked to the GP health record and combine clinical and non-clinical recommendations as part of a shared decision-making process that involves staff from across each practice, including GPs, nurses, pharmacists, healthcare assistants, health and wellbeing coaches and social prescribing link workers.  Patients at risk of cardiovascular disease will be able to conveniently access their personalised plan of care and support from their GP practice through a mobile app that enables them to proactively manage their health through daily actions, educational articles and videos, and information on services in their community.
&nbsp;
 The contract comes off the back of research and development carried out across Cheshire and the North West of England, carried out by Healum in partnership with Vernova CIC, supported by the National Institute for Health Research Greater Manchester team and evaluated by Dr Adrian Heald, Clinical Research Fellow at Manchester University and Consultant Endocrinologist at Salford Royal Foundation Hospital.
&nbsp;
 This contract enables Healum to expand the NHS partners in its research consortium to include Howbeck Healthcare, Lancashire and South Cumbria NHS Integrated Care Board and to increase the number of GP Practices that can access its solution. Additional support from Innovation Agency North West and Health Innovation Network will enable Healum to shape its programme of real-world testing and health economic analysis to demonstrate impact for patients, healthcare professionals and the system as a whole.
&nbsp;
 The contract has been awarded by the Accelerated Access Collaborative (AAC), which is a partnership between patient groups, government bodies, industry and the NHS hosted by NHS England, through SBRI Healthcare. It marks a renewed focus on tackling CVD through Improving current prevention strategies through use of data and personalised approaches and in empowering patients to manage their own conditions through targeted engagement and support.
&nbsp;
 The AAC has awarded a small number of contracts to the most innovative companies in the UK that can have the biggest real-world impact within the NHS system for cardiovascular disease.
&nbsp;
 Matt Whitty, CEO of the AAC, said “These awards will help the NHS to develop new technologies and solutions to address some of the biggest healthcare challenges facing society. We have selected these innovations because they have the potential to make a big difference to patients. By supporting the most promising innovations the NHS will continue to evolve, helping meet more patients’ needs and encouraging more innovators to come forward with ideas that make a difference.”
&nbsp;
 Jonathan Abraham CEO of Healum said “empowering people each day to make healthier choices through access to personalised proactive care wherever they are and whenever they need lies at the heart of our vision. This NHS contract is a validation of our evidence to date, the value of our product and its potential to impact the lives of millions of people. We look forward to working with our partners in the NHS to ease the burden on primary care and to improve outcomes for patients across the UK.”
&nbsp;
 <a href="https://sbrihealthcare.co.uk/news/the-accelerated-access-collaborative-through-sbri-healthcare-awards-3-3-million-to-accelerate-cardiovascular-disease-cvd-innovations/">Link to the full release from SBRI</a>

New blog post

Header style here, with flexibility to use any H style

Related Resource

Journal of Diabetes Nursing Publication

Cardiovascular Endocrinology and Metabolism Journal Publication

Request a meeting now to discover how Healum can help you